Relay Therapeutics Insider Sells 21,000 Shares for $166,700 After 65% Run

Company Overview - Relay Therapeutics is a clinical-stage biotechnology company focused on precision small molecule therapies using computational modeling and structure-based drug design to address unmet needs in oncology and genetic diseases [1] - The company has a pipeline of innovative candidates and strategic collaborations with industry leaders, positioning it to advance next-generation targeted therapies [1] Business Model - Relay Therapeutics operates a clinical-stage biotechnology business model, generating revenue primarily through collaboration and license agreements with partners such as Genentech and D.E. Shaw Research, with future revenue expected from product commercialization [2] Insider Transactions - Donald A. Bergstrom, President of R&D at Relay Therapeutics, sold 21,581 shares for approximately $166,700 on January 27 and 28, 2026, as disclosed in the SEC Form 4 filing [5] - This transaction represented 4.89% of Bergstrom's direct ownership, significantly higher than the recent median percentage of holdings disposed per open-market sale [4] - The sale was primarily to cover income tax withholding obligations after the vesting of restricted stock units (RSUs), indicating that it was not a discretionary sale [6] Stock Performance - Relay Therapeutics' stock has increased nearly 70% since January 28, 2025, and received a Breakthrough Therapy designation from the FDA for zovegalisib in advanced breast cancer treatment, leading to a 6% stock price increase to $8.65 [6] - The company has received positive attention from Wall Street, with upgrades from Wells Fargo and Oppenheimer, and an analyst consensus rating of moderate buy with an average price target of $16.57 [6] Investment Considerations - Despite the positive developments, Relay Therapeutics was not included in a recent list of the top 10 stocks recommended by the Motley Fool Stock Advisor, which could indicate a cautious approach for potential investors [7]